Abstract
Continuous jejunal levodopa infusion is an increasingly used therapy option in patients with Parkinson’s disease who experience severe fluctuations from oral levodopa. In a number of recent reports polyneuropathy in patients receiving jejunal levodopa infusion was referenced to cobalamin (vitamin B12) deficiency. We describe one of three cases from our hospital with severe subacute polyneuropathy that developed during jejunal levodopa infusion, and occurred despite vitamin substitution therapy and normal vitamin B12 and holotranscobalamin serum levels.
This is a preview of subscription content, log in via an institution to check access.
Referencess
Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, Dal Fante M, Lopiano L, Pezzoli G (2007) Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov Disord 22(8):1145–1149
Cacciapuoti F (2011) Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular disease? Pathogenetic and therapeutical uncertainties. J Thromb Thrombolysis 32(1):82–88. doi:10.1007/s11239-011-0550-4
Ceravolo R, Cossu G, Bandettini di Poggio M, Santoro L, Barone P, Zibetti M, Frosini D, Nicoletti V, Manganelli F, Iodice R, Picillo M, Merola A, Lopiano L, Paribello A, Manca D, Melis M, Marchese R, Borelli P, Mereu A, Contu P, Abbruzzese G, Bonuccelli U (2013) Neuropathy and levodopa in Parkinson’s disease: evidence from a multicenter study. Mov Disord 28(10):1391–1397. doi:10.1002/mds.25585
Jugel C, Ehlen F, Taskin B, Marzinzik F, Müller T, Klostermann F (2013) Neuropathy in Parkinson’s disease patients with intestinal levodopa infusion versus oral drugs. PLoS One 8(6):e66639. doi:10.1371/journal.pone.0066639
Klostermann F, Jugel C, Müller T, Marzinzik F (2012) Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm 119(3):369–372. doi:10.1007/s00702-011-0689-3
Manca D, Cossu G, Murgia D, Molari A, Ferrigno P, Marcia E, Melis M (2009) Reversible encephalopathy and axonal neuropathy in Parkinson’s disease during duodopa therapy. Mov Disord 24(15):2293–2294. doi:10.1002/mds.22807
Meppelink AM, Nyman R, van Laar T, Drent M, Prins T, Leenders KL (2011) Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson’s disease. Mov Disord 26(2):331–334. doi:10.1002/mds.23408
Merola A, Zibetti M, Rizzone MG, Troiano M, Artusi CA, Angrisano S, Cocito D, Lopiano L (2014) Prospective assessment of peripheral neuropathy in duodopa-treated parkinsonian patients. Acta Neurol Scand 129(1):e1–e5. doi:10.1111/ane.12164
Müller T (2008) Role of homocysteine in the treatment of Parkinson’s disease. Expert Rev Neurother 8(6):957–967. doi:10.1586/14737175.8.6.957
Müller T (2010) Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-l-methionine and related mechanisms. Int Rev Neurobiol 95:49–71. doi:10.1016/B978-0-12-381326-8.00004-1
Müller T, Jugel C, Ehret R, Ebersbach G, Bengel G, Muhlack S, Klostermann F (2011) Elevation of total homocysteine levels in patients with Parkinson’s disease treated with duodenal levodopa/carbidopa gel. J Neural Transm 118(9):1329–1333. doi:10.1007/s00702-011-0614-9
Müller T, van Laar T, Cornblath DR, Odin P, Klostermann F, Grandas FJ, Ebersbach G, Urban PP, Valldeoriola F, Antonini A (2013) Peripheral neuropathy in Parkinson’s disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord 19(5):501–507. doi:10.1016/j.parkreldis.2013.02.006
Nyholm D, Nilsson Remahl AIM, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius S-M, Askmark H (2005) Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64(2):216–223
Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13(2):141–149. doi:10.1016/S1474-4422(13)70293-X
Santos-García D, Macías M, Llaneza M, Grande M, de la Fuente-Fernández R (2011) Serum vitamin B (12) and folate levels in Parkinson’s disease patients treated with duodenal levodopa infusion. Mov Disord 26(3):558–559. doi:10.1002/mds.23419
Santos-García D, de la Fuente-Fernández R, Valldeoriola F, Palasí A, Carrillo F, Grande M, Mir P, De Fabregues O, Casanova J (2012) Polyneuropathy while on duodenal levodopa infusion in Parkinson’s disease patients: we must be alert. J Neurol 259(8):1668–1672. doi:10.1007/s00415-011-6396-z
Toth C, Breithaupt K, Ge S, Duan Y, Terris JM, Thiessen A, Wiebe S, Zochodne DW, Suchowersky O (2010) Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 68(1):28–36. doi:10.1002/ana.22021
Urban PP, Wellach I, Faiss S, Layer P, Rosenkranz T, Knop K, Weis J (2010) Subacute axonal neuropathy in Parkinson’s disease with cobalamin and vitamin B6 deficiency under duodopa therapy. Mov Disord 25(11):1748–1752. doi:10.1002/mds.23342
Conflicts of interest
The authors have no conflict of interest to report.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lehnerer, S.M., Fietzek, U.M., Messner, M. et al. Subacute peripheral neuropathy under duodopa therapy without cobalamin deficiency and despite supplementation. J Neural Transm 121, 1269–1272 (2014). https://doi.org/10.1007/s00702-014-1204-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-014-1204-4